Literature DB >> 24182356

Spastic diplegia in children with HIV encephalopathy: first description of gait and physical status.

Nelleke G Langerak1, Jacques du Toit, Marlette Burger, Mark F Cotton, Priscilla E Springer, Barbara Laughton.   

Abstract

AIM: The aim of this study was to explore the physical status and gait patterns of children with spastic diplegia secondary to human immunodeficiency virus encephalopathy (HIVE).
METHOD: A cross-sectional study was conducted on children diagnosed with HIVE and spastic diplegia. Sociodemographic and clinical background information was obtained, followed by three-dimensional gait analysis (3DGA) and a physical examination including assessments of muscle tone, strength, motor control, contractures, and bony deformities of the lower extremities.
RESULTS: Fourteen children (eight males, six females; mean age 5 y 8 mo [SD 9 mo], range 4 y 4 mo-6 y 10 mo) were studied. The cohort was divided into two groups based on distinctive gait patterns. Nine participants in group I showed only limited abnormalities. Group II displayed a more pathological gait pattern including stiff knee and equinus ankle abnormalities. Results of 3DGA, as with the physical examination outcomes, showed increased impairments from proximal to distal (except for hip extension).
INTERPRETATION: This study provides a first description of distinctive gait patterns and related physical characteristics of children with HIVE and spastic diplegia. Further research is necessary.
© 2013 Mac Keith Press.

Entities:  

Mesh:

Year:  2013        PMID: 24182356     DOI: 10.1111/dmcn.12319

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  2 in total

Review 1.  HIV-1 proteins, Tat and gp120, target the developing dopamine system.

Authors:  Sylvia Fitting; Rosemarie M Booze; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

2.  Pattern of Cerebral Palsy Among Sudanese Children Less Than 15 Years of Age.

Authors:  Karimeldin Salih
Journal:  Cureus       Date:  2020-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.